Wegovy's Immediate Effects: What Your Body Notices First

Step 1: The first 48 hours, the gut signals something new

Within hours of the first 0.25 mg injection, semaglutide begins binding to GLP-1 receptors in the gut, brainstem and hypothalamus. Gastric emptying slows, food leaves the stomach more gradually than it usually does. This single change can produce a noticeable sense of fullness after eating amounts that would not normally satisfy, even at the lowest starting dose.

Most people do not feel dramatic change immediately. What they often do notice is queasiness in the hours after injection, a slight reluctance to finish a plate, or feeling full faster than expected. These early gut signals are the medicine working as intended. They are not side effects to push through, they are the physiological response the GLP-1 mechanism is designed to produce.

There is a common misconception that if you feel fine in the first 24 hours, the medicine is not working. That is rarely the case. The response in those first two days is often subtle, and that is normal. Nausea, when it arrives, typically peaks around days two to four of the first injection cycle, then eases as the body adapts. According to the NHS semaglutide medicines guide, nausea and vomiting are among the most commonly reported effects at the start of treatment, generally mild to moderate in severity.

Step 2: Days four to fourteen, appetite shifts and the adjustment window

By the end of the first week, the appetite-reducing signal tends to become more consistent. Food feels less urgent. The internal prompts to snack, or to eat past the point of comfort, quieten. This is not a dramatic switch, it is closer to a gradual dimming of hunger's background noise.

For some people, the gastrointestinal effects remain present through this window: intermittent nausea, burping, constipation or loose stools. These are not universal; a meaningful proportion of people start with minimal disruption. Where symptoms do appear, they are most pronounced during this adjustment phase and tend to settle before the next dose increase at the four-week mark.

Understanding the brain-level appetite signals that semaglutide influences can make this window easier to interpret. The hypothalamus, which coordinates hunger and satiety, receives GLP-1 signals that reduce the reward value of food. People often describe this not as feeling sick, but as simply being uninterested in eating, a genuinely unfamiliar experience for many.

Energy levels can fluctuate. Some people report mild fatigue or light-headedness early on, linked to reduced calorie intake rather than the medicine directly. Staying well hydrated and maintaining protein intake helps considerably.

Step 3: Weeks two to four, when physical changes begin

Sustained appetite reduction translates into lower calorie intake, and this is where early weight change typically begins. It is rarely dramatic in the first four weeks, the 0.25 mg dose was not designed to produce maximum effect. It is setting the stage for the titration steps that follow.

Clinical trial data from the STEP 1 study, published in the New England Journal of Medicine, recorded an average body weight reduction of approximately 15% over 68 weeks at the 2.4 mg maintenance dose, results that accumulated across the full titration schedule, not the first month alone. The early weeks are foundational, not the headline.

Some people also notice early changes in food preferences during this period, finding rich or fatty foods less appealing than usual. This is an extension of the same central appetite-signalling process, and for many it is one of the more striking immediate effects. If you want a fuller picture of how these effects develop over time, this overview of semaglutide's effects covers the progression across the treatment journey.

What the immediate effects do not include

It is worth being straightforward about what Wegovy's immediate effects are not. Significant weight loss in the first week is unlikely. The medicine does not suppress appetite so completely that eating feels impossible, most people can and should continue eating regularly, focusing on smaller portions and adequate nutrition. The starting dose is deliberately conservative, and any prescriber or aftercare team will tell you the same.

If you experience severe or persistent stomach pain that radiates to the back, with or without vomiting, seek medical help promptly, this can be a sign of pancreatitis, a known but uncommon serious reaction flagged in MHRA safety communications. Symptoms that concern you should always be discussed with your prescriber or clinical team rather than managed alone.

Side effects in the early weeks can also prompt questions about the longer-term experience. What happens to the body after stopping semaglutide is a separate question, one worth understanding before starting. For context on what Wegovy costs through a private pharmacy in the UK, that is covered separately; what matters first is knowing what to expect from treatment itself.

If you are considering Wegovy and want to speak with a prescriber about whether it suits your circumstances, start your free consultation with the nume clinical team, reviewed the same day by a GPhC-registered prescriber, not automated software.